Neuroleptic malignant syndrome and hydroxylase gene mutations: No association with CYP2D6A or CYP2D6B

Psychiatric Genetics

Volumn 7, Issue 3, 1997, Pages 127-129

  Kawanishi, C ^a   Hanihara, T ^a   Maruyama, Y ^a   Matsumura, T ^a   Onishi, H ^a   Inoue, K ^a   Sugiyama, N ^a   Suzuki, K ^a   Yamada, Y ^a   Kosaka, K ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Association study; CYP2D6; Debrisoquine 4 hydroxylase; Genetics; Neuroleptic malignant syndrome; Neuroleptics; Poor metabolizer; Side effect

Indexed keywords

OXYGENASE;

ALLELE; ARTICLE; CLINICAL GENETICS; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEUROLEPTIC MALIGNANT SYNDROME; PHENOTYPE; PRIORITY JOURNAL;

EID: 9844240508     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041444-199723000-00007     Document Type: Article

References (19)

1. The American Psychiatric Association (1995) Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Association, Washington, DC, USA.
2. Armstrong M, Daly AK, Cholerton S, Bateman DN and Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet, 339, 1017-1018.
3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K and Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA and Cell Biology, 10, 545-558.
4. Dahl M-L and Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics, 3, 61-70.
5. Daly AK, Armstrong M, Monkman SC, Idle ME and Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotype. Pharmacogenetics, 1, 33-41.
6. Dawson E, Powell JF, Nöthen MM, Crocq M-A, Lanczik M, Körner J, Rietschel M, van Os J, Wright P and Gill M (1994) An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatric Genetics, 4, 215-218.
7. Deuschl G, Oepen G and Hermle L (1987) Neuroleptic malignant syndrome: Observations on altered consciousness. Pharmacopsychiatry, 20, 168-170.
8. Gonzalez FJ and Idle JR (1994) Pharmacogenetic phenotyping and genotyping: Present status and future potential. Clinical Pharmacokinetics, 26, 59-70.
9. Iwahashi K (1994) CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biological Psychiatry, 36, 781-782.
10. Kimura S, Umeno M, Skoda RC, Meyer US and Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. American Journal of Human Genetics, 45, 889-904.
11. Kurth MC and Kurth JH (1993) Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. American Journal of Medical Genetics, 48, 166-168.
12. Otani K, Horiuchi M, Kondo T, Kaneko S and Fukushima Y (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry, 158, 850-853.
13. Pope HG, Keck PE and McElroy SL (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry, 143, 1227-1233.
14. Ram A, Cao Q, Keck PE, Pope HG, Otani K, Addonizio G, McElroy SL, Kaneko S, Redlichova M, Gershon ES and Gejman PV (1995) Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Americal Journal of Medical Genetics, 60, 228-230.
15. Rosebush PI and Stewart TD (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146, 717-725.
16. Sexena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N and Weiffenbach B (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Human Molecular Genetics, 3, 923-926.
17. Siddons MA, Pickering-Brown SM, Mann DMA, Owen F and Cooper PN (1996) Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Neuroscience Letters, 208, 65-68.
18. Smith AD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Williams AC, Spurr NK and Wolf CR (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1375-1377.
19. Ueno S, Otani K, Kaneko S, Koshiro K, Kondoh K, Kotani Y and Sano A (1996) Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome. Biological Psychiatry, 40, 72-74.